Search

BACKGROUND: Aspartate aminotransferase (AST), an indicator of liver cell damage, was related to the prognosis of certain malignant tumors. OBJECTIVE: This study examined the predictive value of AST in patients with extranodal natural killer/T cell lymphoma (ENKTL). METHODS: We reviewed 183 cases diagnosed with ENKTL and selected 26 U/L as the optimum cut-off value of AST. We used the univariate and multivariate Cox regression to compare the different AST groups' overall survival (OS) and progression-free survival (PFS). RESULTS: Prior to propensity score matching (PSM), Kaplan-Meier analysis showed that patients in the low AST subgroup had better OS and PFS than the high AST subgroup. Multivariate analysis revealed that AST was an independent indicator for prognosis. After PSM, the low AST subgroup maintained a significantly better OS and PFS than the high AST subgroup. CONCLUSION: AST might represent a significant prognostic marker for ENKTL patients. [ABSTRACT FROM AUTHOR]

BACKGROUND: At present, peripheral blood markers are easily accessible information and clinically valuable prognostic indicators in extranodal nasal-type natural killer/T-cell lymphoma (ENKTCL). Nevertheless, the role of its comprehensive score in ENKTCL remains to be determined. OBJECTIVE: Therefore, this study aimed to investigate the prognostic effect of the peripheral inflammation score on ENKTCL. METHODS: The retrospective study included 183 patients with ENKTCL. Univariate Cox regression analyses and least absolute shrinkage and selection operator (LASSO) Cox regression were used to construct the inflammation-related prognostic index named Risk. Univariate and multivariate Cox regression analyses and regression adjustment with propensity score matching (PSM) were used to evaluate the prognostic ability of risk. The performance of the modified nomogram-revised risk index (NRI) by integrating risk was evaluated with the area under the time-dependent receiver operating characteristic (ROC) curve (AUC), decision curve analysis (DCA), and integrated Brier score (IBS). RESULTS: The risk cut-off value, constructed by the lymphocyte count, platelet count, albumin level, LMR, and PNI, was - 1.3486. Before PSM, multivariate analysis showed that risk was significantly associated with OS (HR = 2.577, 95% CI = 1.614–4.114, P < 0.001) and PFS (HR = 2.679, 95% CI = 1.744–4.114, P < 0.001). After PSM adjustment, risk was still an independent factor for OS (HR = 2.829, 95% CI = 1.601–5.001, P < 0.001) and PFS (HR = 2.877, 95% CI = 1.735–4.770, P < 0.001). With the NRI, the modified NRI by integrating risk increased the AUC and clinical net benefit and decreased the IBS. CONCLUSIONS: Risk is an easily accessible and inexpensive indicator that may be used as a prognostic marker and could improve NRI predictive power in patients with ENKTCL. [ABSTRACT FROM AUTHOR]

Extranodal Natural Killer/T Cell Lymphoma Nasal Type (EN-NK/T-CL-NT) is a rare type of non-Hodgkin lymphoma in which the lesion is usually located in the upper respiratory tract, such as nasal cavity, palate, and nasopharynx. In addition, the primary lesion of EN-NK/T-CL-NT can rarely originate in extranasal sites such as the skin, gastrointestinal tract, testicles, central nervous system, and lungs. We describe an 82-year-old male smoker was brought to the hospital with 8 months of fever, cough, sputum production, chest pain, and chest tightness. Computed tomography (CT) of the chest showed subpleural high-density shadow in the lower lobe of the right lung with unclear borders and surrounding patchy ground-glass shadow. Initially, the patient's right lower lobe lesion progressed after receiving anti-inflammatory treatment. He subsequently underwent two computerized tomography (CT)-guided percutaneous transthoracic needle aspiration biopsies and a bronchoscopy, but no tumor cells were found. Through multidisciplinary team discussions, the patient was then transferred to the department of cardiothoracic surgery for right lower lobectomy. Finally, extranodal natural killer/T-cell lymphoma (ENKTCL), nasal type, was confirmed by pathology of the surgical specimen. The diagnosis of primary pulmonary ENKTCL was made because no evidence other than extrapulmonary site was found at the time of diagnosis and treatment. Here we report a case of primary pulmonary extranodal natural killer/T-cell lymphoma of nasal type presenting as pneumonia in the right lower lobe and enhance the understanding of the disease.

Extranodal Natural Killer/T Cell Lymphoma Nasal Type (EN-NK/T-CL-NT) is a rare type of non-Hodgkin lymphoma in which the lesion is usually located in the upper respiratory tract, such as nasal cavity, palate, and nasopharynx. In addition, the primary lesion of EN-NK/T-CL-NT can rarely originate in extranasal sites such as the skin, gastrointestinal tract, testicles, central nervous system, and lungs. We describe an 82-year-old male smoker was brought to the hospital with 8 months of fever, cough, sputum production, chest pain, and chest tightness. Computed tomography (CT) of the chest showed subpleural high-density shadow in the lower lobe of the right lung with unclear borders and surrounding patchy ground-glass shadow. Initially, the patient's right lower lobe lesion progressed after receiving anti-inflammatory treatment. He subsequently underwent two computerized tomography (CT)-guided percutaneous transthoracic needle aspiration biopsies and a bronchoscopy, but no tumor cells were found. Through multidisciplinary team discussions, the patient was then transferred to the department of cardiothoracic surgery for right lower lobectomy. Finally, extranodal natural killer/T-cell lymphoma (ENKTCL), nasal type, was confirmed by pathology of the surgical specimen. The diagnosis of primary pulmonary ENKTCL was made because no evidence other than extrapulmonary site was found at the time of diagnosis and treatment. Here we report a case of primary pulmonary extranodal natural killer/T-cell lymphoma of nasal type presenting as pneumonia in the right lower lobe and enhance the understanding of the disease., Competing Interests: No one in the manuscript has a conflict of interest., (© 2024 The Authors. Published by Elsevier Ltd.)